SCYNEXIS, Inc.
SCYX Healthcare Drug Manufacturers Specialty & Generic
SCYNEXIS, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 million, up 449.9% from fiscal 2024. In the quarter to June 2026, revenue fell 8.56%, EPS grew 156.3% and free cash flow fell 98.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow SCYX
SCYNEXIS, Inc. (SCYX) Altman Z-score
SCYNEXIS, Inc.'s Altman Z-score for fiscal 2025 is −7.02, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −7.02 | (1.52) |
| FY2024 | −5.50 | (6.54) |
| FY2023 | 1.04 | 9.63 |
| FY2022 | −8.59 | (5.01) |
| FY2021 | −3.58 | 4.33 |
| FY2019 | −7.91 | (1.93) |
| FY2018 | −5.98 | (0.26) |
| FY2017 | −5.72 | (2.55) |
| FY2016 | −3.17 | (4.22) |
| FY2015 | 1.05 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.59 | — | 0.70 | |
| Retained earnings / total assets | (6.52) | — | −9.13 | |
| EBIT / total assets | (0.27) | — | −0.90 | |
| Market value of equity / total liabilities | 3.27 | — | 1.96 | |
| Sales / total assets | 0.35 | — | 0.35 | |
| Altman Z-score | Distress zone | −7.02 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −13.88 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ZYBT Zhengye Biotechnology Holding Limited compare | 1.5× |
| INCR InterCure Ltd. compare | 0.1× |
| CPHI China Pharma Holdings, Inc. compare | −2.2× |
| SCYX SCYNEXIS, Inc. | −7.0× |
| RMTI Rockwell Medical, Inc. compare | −7.4× |
| IXHL Incannex Healthcare Inc. compare | −13.2× |
| TLPH Talphera, Inc. compare | −20.7× |
| TXMD TherapeuticsMD, Inc. compare | −34.4× |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets